210 related articles for article (PubMed ID: 8393595)
21. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
Konttinen YT; Bluestein HG; Zvaifler NJ
J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749
[TBL] [Abstract][Full Text] [Related]
22. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts.
Alegre ML; Peterson LJ; Jeyarajah DR; Weiser M; Bluestone JA; Thistlethwaite JR
J Immunol; 1994 Sep; 153(6):2738-49. PubMed ID: 8077678
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
24. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
26. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus.
Boyle TJ; Tamburini M; Berend KR; Kizilbash AM; Borowitz MJ; Lyerly HK
Surgery; 1992 Aug; 112(2):378-86. PubMed ID: 1322566
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes.
Mosier DE; Picchio GR; Baird SM; Kobayashi R; Kipps TJ
Cancer Res; 1992 Oct; 52(19 Suppl):5552s-5553s. PubMed ID: 1327510
[TBL] [Abstract][Full Text] [Related]
28. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
[TBL] [Abstract][Full Text] [Related]
29. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
[TBL] [Abstract][Full Text] [Related]
31. [Ex vivo inducing cultured Epstein-Barr virus specific cytotoxic T lymphocytes and evaluation of their killing effect].
Chen GH; Gu B; Chen F; Wang Y; Qiao M; Liu HW; Feng YF; Dai LJ; Zhu ZL; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1597-601. PubMed ID: 24370055
[TBL] [Abstract][Full Text] [Related]
32. Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.
Gallot G; Vollant S; Vivien R; Clémenceau B; Ferrand C; Tiberghien P; Gaschet J; Robillard N; Vié H
Clin Exp Immunol; 2006 Apr; 144(1):158-68. PubMed ID: 16542378
[TBL] [Abstract][Full Text] [Related]
33. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice.
Buchsbaum RJ; Fabry JA; Lieberman J
Immunol Lett; 1996 Sep; 52(2-3):145-52. PubMed ID: 8905410
[TBL] [Abstract][Full Text] [Related]
34. Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation.
Piovan E; Bonaldi L; Indraccolo S; Tosello V; Menin C; Comacchio F; Chieco-Bianchi L; Amadori A
Leukemia; 2003 Aug; 17(8):1643-9. PubMed ID: 12886254
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy against EBV-lymphoma in recipients of HSCT.
Comoli P; Zecca M; Maccario R
Expert Rev Hematol; 2010 Oct; 3(5):625-32. PubMed ID: 21083478
[TBL] [Abstract][Full Text] [Related]
36. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice.
Coles RE; Boyle TJ; DiMaio JM; Berend KR; Via DF; Lyerly HK
Ann Surg Oncol; 1994 Sep; 1(5):405-10. PubMed ID: 7531601
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
38. Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function.
de Kroon JF; van Bergen CA; de Paus RA; Kluin-Nelemans HC; Willemze R; Falkenburg JH
J Immunother; 1997 Mar; 20(2):101-10. PubMed ID: 9087382
[TBL] [Abstract][Full Text] [Related]
39. Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell-engrafted NOD/SCID/IL-2Rγc null mice.
Thomas S; Klobuch S; Sommer M; van Ewijk R; Theobald M; Meyer RG; Herr W
Exp Hematol; 2014 Jan; 42(1):28-38.e1-2. PubMed ID: 24120693
[TBL] [Abstract][Full Text] [Related]
40. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
